About
jcpc@jinchengpharm.com
Company profile
Location：Home - Company profile Shandong Jincheng Pharmaceutical Group Co., Ltd. was established in 2004, and is headquartered in Zibo City, Shandong Province. In 2011, Jincheng Pharma was listed on GEM of Shenzhen Stock Exchange (Stock code SZ300233). Now it is a National High-tech Enterprise with more than 3800 employees and more than 30 participating holding companies around the world (including Italy, Beijing, Shanghai, Hangzhou, Zhongshan). Jincheng Pharma mainly engaged in the R&D, production and marketing of pharmaceutical intermediates, APIs, finished pharmaceutical products, and general health products, which is the world's largest production and research base of cephalosporins side-chain intermediates and bio-fermentation API Glutathione, domestic well-known manufacturer of anti-infection and gynecological preparations, and has the most abundant cephalosporin antibiotics and gynecology full-life-cycle series products in China. The company is a burgeoning entire-industry-chain innovative pharmaceutical and health industry group, with international layout and integrating research, manufacturing and marketing.
The company adheres to the strategic development orientation of basing on "general medicine" and expanding "general health", and focuses on products for the therapeutic areas of anti-infection, gynecology, antiviral, chronic disease, pediatrics, hormone and immune regulation, liver disease. We provide more than 80 pharmaceutical products, such as APIs, injections, tablets, capsules, soft capsules, powders, sprays, creams, etc., based on ten manufacturing sites in “Beijing, Shanghai, Guangzhou and Shandong Province”. It has created many famous brand products in the industry, such as Jincheng cephalosporin intermediate, Golden quality antibiotic series, Langyi gynecology series, Glutathione API and health care product series. There are 2 sterile powder injections won the bid for the national centralized procurement of drugs, more than 10 products passed the consistency evaluation.
The company has established long-term cooperative relationships with hundreds of pharmaceutical companies around the world, and has formed a global market layout with the domestic market as the main body, Europe, America and India market as the leading exporters, and extending to the markets of Japan, South Korea and ASEAN. We provide pharmaceutical products and health products for more than 30 countries and regions, and more than 3000 domestic medical institutions and chain drugstores, bring health to hundreds of millions of patients every year.
Relying on years of accumulation in technology, talents, and industrialization, the company has formed multiple core competitiveness in technology and management innovation, such as safe and green environmental protection technology, quality management, cost control, and lean management. It has a R&D team of more than 200 people, led by Taishan industry leading talent, focusing on chemical synthesis, synthetic biology and finished pharmaceutical products, etc., and has built 3 National-level Scientific Research Platforms, 5 Provincial-level Scientific Research Platforms, and 6 Provincial-level Enterprise Technology Centers. There are 3 manufacturing sites for cephalosporin pharmaceutical intermediates, 2 manufacturing sites for chemical APIs, 2 manufacturing sites for biosynthetic APIs, and 3 manufacturing sites for finished pharmaceutical products. The sites of finished pharmaceutical products have 13 biopharmaceutical production lines such as automatic fermentation, separation and purification, sterile separation packed powder injection, and 13 pharmaceutical products production lines such as powder, capsules, tablets, cream, granules, and sterile powder injections. The company has won more than 300 honors such as the National Science and Technology Progress prize and the Best GEM Listed Company, and has been successfully selected into the FTSE Russell index, ranked among the " Double top 100" of China's medical industry and China's pharmaceutical industry, and is making great strides towards the development vision of "Becoming an innovative leading enterprise in the pharmaceutical and health industry".
The company is committed to the overall strategy of "Focus on main business; Pursue resource integration; Focus on innovation". In the future, we will continue to aim at high-quality development, with the goal of meeting customer and clinical needs, focus on high-end pharmaceutical and chemical products, high-threshold characteristic APIs and bioactive products, high-level generic drugs and improved new drugs. At the same time, the company is committed to expanding CMO/CDMO business, actively exploring the field of new drugs, improving the innovation system of the entire-industry-chain, developing new models of pharmaceutical R&D, and striving to build the company into a world-renowned and nationally leading innovative pharmaceutical and health industry group.